Skip to main content
SpringerLink
Log in

Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor

  • Original Articles
  • Immunomodulation, Low-Dose Chemotherapy, IL-10, IFNγ, CTL
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

The current studies demonstrate that MOPC-315 tumor cells secrete large amounts of interleukin-10 (IL-10), which contributes to the inhibitory activity of MOPC-315 culture supernatants for the in vitro generation of antitumor cytotoxicity by MOPC-315-“immune” spleen cells. Moreover, addition of neutralizing monoclonal anti-IL-10 antibody to the in vitro stimulation cultures of cells from the tumor infiltrated spleens of mice bearing a large MOPC-315 tumor resulted in the generation of enhanced anti-MOPC-315 cytotoxicity. In contrast, addition of monoclonal anti-IL-10 antibody to the in vitro stimulation cultures of splenic cells from mice that are in the final stages of immune-mediated tumor eradication as a consequence of low-dose melphalan (l-phenylalanine mustard; L-PAM) therapy (and whose spleens no longer contain metastatic tumor cells) did not lead to enhancement in the in vitro generation of antitumor cytotoxicity. The cessation of IL-10 secretion as a consequence of low-dose L-PAM therapy of MOPC-315 tumor bearers was found to be accompanied by the acquisition of the ability to secrete interferon γ (IFNγ) by the splenic cells. In addition, by day 2 after low-dose L-PAM therapy a drastic decrease in the amount of IL-10 secreted by the s.c. tumor nodules was noted, which preceded the accumulation of tumor-infiltrating lymphocytes capable of secreting IFNγ. Thus, low-dose L-PAM therapy of mice bearing a large MOPC-315 tumor leads to a shift in cytokine production from a Th2-type cytokine to a Th1-type cytokine, and it is conceivable that this shift in cytokine production plays an important role in the low-dose L-PAM-induced acquisition of antitumor immunity by hitherto immunosuppressed mice bearing a large MOPC-315 tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Askenase PW, Hayden BJ, Gershon RK (1975) Augmentation of delayed type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 141:697

    PubMed  Google Scholar 

  2. Awwad M, North RJ (1989) Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T cells. Cancer Res 49:1649

    PubMed  Google Scholar 

  3. Bajarano M-T, Waal Malefyt R de, Abrams JS, Bigler M, Baccetta R, de Vries JE, Roncarolo M-G (1992) Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 4:1389

    PubMed  Google Scholar 

  4. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA (1993) Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177:57

    PubMed  Google Scholar 

  5. Ben-Efraim S, Bocian RC, Mokyr MB, Dray S (1983) Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol Immunother 15:101

    PubMed  Google Scholar 

  6. Benjamin D, Knobloch TJ, Dayton MA (1992) Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 80: 1289

    PubMed  Google Scholar 

  7. Berd D, Maguire HC, Mastrangelo MJ (1985) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572

    Google Scholar 

  8. Berd D, Maguire HC, McCue P, Mastrangelo MJ (1990) Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 8:1858

    PubMed  Google Scholar 

  9. Berd D, Murphy G, Maguire HC, Mastrangelo MJ (1991) Immunization with haptenized autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res 51:2731

    PubMed  Google Scholar 

  10. Chan SH, Perussia B, Gupta JW, Kobayasi M, Pospisil M, Young HA, Wolf SF, Young D, Clark SC, Trinchieri G (1991). Induction of interferon γ by natural killer stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 173:869

    PubMed  Google Scholar 

  11. Ehrke MJ, Maccubbin D, Ryoyama K, Cohen SA, Mihich E (1986) Correlation between Adriamycin-induced augmentation of interleukin-2 production and of cell-mediated cytotoxicity in mice. Cancer Res 46:54

    PubMed  Google Scholar 

  12. Fiorentino DE, Bond MW, Mosmann TR (1989) Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170:2081

    PubMed  Google Scholar 

  13. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Singaglia F, Chizonnite R, Gubler U Stern AS (1991) Regulation of human lymphocyte proliferation by a heterodimeric cytokine IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147:874

    PubMed  Google Scholar 

  14. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, Moore KW, Howard M (1990) Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X-linked immunodeficiency B cells. J Exp Med 172:1625

    PubMed  Google Scholar 

  15. Hengst JCD, Mokyr MB, Dray S (1980) Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. Cancer Res 40:2135

    PubMed  Google Scholar 

  16. Hengst JCD, Mokyr MB, Dray S (1981) Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41:2163

    PubMed  Google Scholar 

  17. Hoon DB, Foshag LJ, Nizze AS, Bohman R, Morton DL (1990) Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 50:5358

    PubMed  Google Scholar 

  18. Issekutz TB (1990) Effect of 6 different cytokines on lymphocyte adherence to microvascular endothelium and in vivo lymphocyte migration in the rat. J Immunol 144:2140

    PubMed  Google Scholar 

  19. Lattime EC, Mastrangelo MJ, Berd D (1994) Human metastatic melanoma lesions and cell lines express mRNA for IL-10. Proc Am Assoc Cancer Res 35:489

    Google Scholar 

  20. Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oertgen HF, Old L (1987) Vaccine containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci (USA) 84:2911

    Google Scholar 

  21. Maguire HC, Ettore VL (1967) Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol 48:39

    PubMed  Google Scholar 

  22. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in the treatment of disseminated melanoma. J Clin Oncol 6:409

    PubMed  Google Scholar 

  23. Mokyr MB, Barker E (1986) Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan treated MOPC-315 tumor bearers. Cancer Immunol Immunother 23:11

    PubMed  Google Scholar 

  24. Mokyr MB, Braun DP, Usher D, Reiter H, Dray S (1978) The development of in vitro and in vivo antitumor cytotoxicity in noncytotoxic MOPC-315 tumor bearer spleen cells “educated” in vitro with MOPC-315 tumor cells. Cancer Immunol Immunother 4:143

    Google Scholar 

  25. Mokyr MB, Barker E, Weiskirch L, Takesue BY, Pyle JM (1989) Importance of Lyt 2+ T cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res 49:4597

    PubMed  Google Scholar 

  26. Mokyr MB, Rubin MA, Newell KA, Prokhorova A, Bluestone JA (1993) Involvement of TCR-Vβ8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low-dose melphalan. J Immunol 151:4838

    PubMed  Google Scholar 

  27. Moore KW, O'Garra A, Waal Malefyr R de, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165

    PubMed  Google Scholar 

  28. Morikawa K, Hosokawa M, Hamada J, Sugawara M, Kobayashi H (1985) Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma. Cancer Res 45:1502

    PubMed  Google Scholar 

  29. Mosmann TR, Schumacher JH, Fiorentino DF, Leverah J, Moore KW, Bond M (1990) Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new TH2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay. J Immunol 145:2938

    PubMed  Google Scholar 

  30. Nagarkatti M, Toney DM, Nagarkatti PS (1989) Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res 49:6587

    PubMed  Google Scholar 

  31. North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90

    PubMed  Google Scholar 

  32. O'Garra A, Stapleton G, Dhar V, Pearce M, Schumacher J, Rupo H, Barbis D, Stall A, Cupp J, Moore K, Vieira P, Mosmann T, Whitmore A, Arnold L, Haughton G, Howard M (1990) Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol 2:821

    PubMed  Google Scholar 

  33. O'Garra A, Chang R, Go N, Hasting R, Haughton G, Howard M (1992) Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol 22:711

    PubMed  Google Scholar 

  34. Ozer H, Cowens JW, Colvin M, Nussbaum-Blumenson A, Sheedy D (1982) In vitro effects of 4-hydroperoxy-cyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration. J Exp Med 155:276

    PubMed  Google Scholar 

  35. Parker CM, Cepek KL, Russell GJ, Shaw SK, Posnett DM, Schwarting R, Brenner MB (1992) A family of β7 integrins on humoral mucosal lymphocytes. Proc Natl Acad Sci USA 89:1924

    PubMed  Google Scholar 

  36. Powrie F, Menon S, Coffman RL (1993) Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 23:3043

    PubMed  Google Scholar 

  37. Rubin M, Mokyr MB (1993) Characterization of the exogenous IL-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers. Cancer Immunol Immunother 36:37

    PubMed  Google Scholar 

  38. Sahasrabudhe DM, deKernion JB, Pontes JE, Ryan DM, O'Donnell RW, Marquis DM, Mudholkar GS, McCune CS (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Modif 5:581

    Google Scholar 

  39. Santos GW, Owens AH, Sensenbrenner LL (1964) Effects of selected cytotoxic agents on antibody production in man; a preliminary report. Ann NY Acad Sci 114:404

    PubMed  Google Scholar 

  40. Siegel JP (1988) Effects of interferon-γ on the activation of human T lymphocytes. Cell Immunol 111:461

    PubMed  Google Scholar 

  41. Takesue BY, Pyle JM, Mokyr MB (1990) Importance of tumorspecific cytotoxic CD8+ T cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy. Cancer Res 50:7641

    PubMed  Google Scholar 

  42. Trinchieri G (1993) Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 14:335

    PubMed  Google Scholar 

  43. Wallick SC, Figari IS, Morris RE, Levinson AD, Palladino MA (1990) Immunoregulatory role of transforming growth factor β (TGF-β) in development of killer cells: comparison of active and latent (TGF-β1)

  44. Weiskirch LM, Baumgartel BA, Barker E, Mokyr MB (1991) Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315 tumor bearers. Cancer Immunol Immunother 32:353

    PubMed  Google Scholar 

  45. Weiskirch LM, Bar-Dagan Y, Mokyr MB (1994) Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor-eradication following low-dose melphalan therapy. Cancer Immunol Immunother 38:215

    PubMed  Google Scholar 

  46. Ye Q-W, Mokyr MB, Pyle JM, Dray S (1984) Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 16:162

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, University of Illinois at Chicago, 1819 West Polk Street, 60680, Chicago, Illinois, USA

    Leonid Gorelik, Anna Prokhorova & Margalit B. Mokyr

Authors
  1. Leonid Gorelik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Prokhorova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Margalit B. Mokyr
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by research grant IM-435 from the American Cancer Society and CA54413 from the National Cancer Institute

In partial fulfillment of the requirements for the Doctor of Philosophy Degree

Recipient of career development award CA-01350 from the National Cancer Institute

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gorelik, L., Prokhorova, A. & Mokyr, M.B. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 39, 117–126 (1994). https://doi.org/10.1007/BF01525317

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01525317

Key words

Search

Navigation